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Abstract Calcium channel blocker toxicity has been
associated with marked hyperglycemia responsive only
to high-dose insulin therapy. The exact mechanism(s) of
this induced hyperglycemia has not been clearly delineated. The glucose transporter GLUT1 is expressed in a
wide variety of cell types and is largely responsible for a
basal level of glucose transport. GLUT1 also is activated
by cell stress. The specific purpose of this study was to
investigate the effects of the calcium channel blocker
verapamil on the glucose uptake activity of GLUT1 in
L929 fibroblasts cells. Dose-dependent effects of verapamil on glucose uptake were studied using L929
fibroblast cells with 2-deoxyglucose. Verapamil had a
dose-dependent inhibitory effect on both basal and stressactivated transport activity of GLUT1. Basal activity was
inhibited 50% by 300 μM verapamil, while 150 μM
verapamil completely inhibited the activation induced by
the stress of glucose deprivation. These effects were
reversible and required verapamil to be present during
the stress. Alteration of calcium concentrations by
addition of 5 mM CaCl2 or 4 mM EDTA had no effect
on verapamil action. This study reveals the unique finding
that verapamil has inhibitory effects on the transport
activity of GLUT1 independent of its effects on calcium
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concentrations. The inhibition of GLUT1 may be one of
the contributing factors to the hyperglycemia observed in
CCB poisoning.
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Introduction
The incidence of calcium channel blocker (CCB) poisoning
and related deaths has been steadily increasing over the past
decade [1, 2]. The effects of CCBs at toxic doses are largely
ascribed to four mechanisms: (1) inhibition of calcium
influx through L-type calcium channels, (2) inhibition of
myocardial fast sodium channels, (3) inhibition of insulin
release from pancreatic islet cells producing hypoinsulemia
and hyperglycemia, and (4) inhibition of glucose uptake in
peripheral tissues [3–9]. The CCB-induced decreased
contractility can generate a shock state with an accompanying reduction in cell perfusion. Of particular importance
is that this reduction of oxygen delivery triggers myocardial
cells to switch from free fatty acids, the major fuel at
normal aerobic conditions, to glucose [10]. The switch to
glucose in cardiac cells occurs as both insulin release and
peripheral insulin sensitivity is compromised [5, 7, 10–12].
Thus, glucose uptake is inhibited precisely as the cardiac
cells need for glucose increases. This combination can
contribute to the clinical effects described in the literature
during CCB toxicity [5].
The hyperglycemia that frequently accompanies CCB
poisoning is a strong indicator of the severity of the toxicity
[13]. Often, the hyperglycemia cannot be resolved by
physiological infusions of insulin, but requires high-dose
insulin therapy (HDIT) [6]. Based on positive data from
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both animals and human case studies, HDIT (with or
without concomitant infusions of glucose) is now gaining
acceptance as an effective treatment strategy for CCB
overdoses [11, 14–16]. However, there are few studies that
document the extent of the CCB-dependent glucose uptake
inhibition or that identify the molecular mechanisms
responsible. Based on the limited available experimental
evidence, the 2005 American Heart Association guidelines
pertaining to emergency cardiovascular care list the use of
glucose/insulin infusion in CCB toxicity as class indeterminate [17, 18]. Thus, a clearer understanding of the
mechanism for the CCB-inhibited glucose uptake will
support evidence-based HDIT and may help to further
delineate treatment strategies for CCB toxicity.
The CCB-induced hyperglycemia suggests that high
concentrations of CCBs compromise peripheral glucose
uptake. A family of passive transporters known as the
GLUTs mediates glucose uptake in mammalian system.
There are 13 members of this family and cells often express
more than on type of GLUT [19]. Two members of this
family have received wide research attention: GLUT4,
which is the insulin-regulated transporter that is found
largely in muscle and fat tissue, and GLUT1, which has
ubiquitous distribution, but is uniquely responsible for
glucose transport into erythrocytes and across the blood
brain barrier. Both of these transporters are subjected to
acute regulation. For GLUT4, it has been well established
that both exercise and insulin stimulate glucose uptake by
an enhanced translocation of GLUT4 from internal stores to
the cell surface membrane. GLUT1, on the other hand, is
generally not sensitive to insulin or exercise, but can be
activated within minutes by cell stressors such as hypoxia,
hypoosmolarity, respiratory inhibitors, and glucose deprivation [20–25]. The mechanism of this activation is not
well understood, but it is clear that it is not caused by a
translocation of GLUT1 to the surface [20, 22].
The effects of CCBs, particularly verapamil, on the
glucose transport activity of the GLUTs have been
investigated. A CCB-dependent inhibition of glucose
uptake has been documented in adipocytes [3, 26, 27],
striated muscle [28], cardiac, and neuronal cells [29]. The
cells or tissues used in these studies expressed more than
one type of GLUT, and thus, the inhibitory activity was
typically attributed to an effect on the most abundant
transporter (GLUT4 for the insulin-sensitive cells). However, muscle tissue contains both GLUT1 and GLUT4
transporters with GLUT1 accounting for 25–40% of
glucose transport under basal (non-insulin) conditions [30,
31]. Given the apparent insulin resistant state induced by
CCBs and their inhibition of GLUT4 translocation [28], the
importance of GLUT1 activity in CCB toxicity cases
would likely be enhanced. The effects of CCBs on
GLUT1 have not been fully described. Therefore, the
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purpose of this investigation was to determine the effects
of verapamil on glucose uptake in L929 fibroblast cells,
cells that only contain GLUT1 transporters [32]. Thus,
any change in glucose uptake in this cell line can clearly
be assigned to effects on GLUT1. Specifically, we
measured the effects of verapamil on both the normal
transport activity of GLUT1 and on the ability to activated
GLUT1 by cell stress (glucose deprivation). In addition,
since verapamil is a calcium channel blocker, we wanted
to determine if these effects were dependent on changing
calcium concentrations.

Methods
Each experiment reported in this study was done with L929
fibroblast cells in a 24-well plate. Experiments were
repeated several times, and results from a representative
experiment are reported. Experimental conditions were
repeated in triplicate or quadruplicate, and glucose uptakes
were measured and reported as nanomoles per 10 min per
well ± standard error. A two-tailed paired t test was used to
show statistical significance. Each experiment had a 30-min
treatment phase followed by a 10-min glucose uptake
phase. In one experiment, to determine if verapamil was
required to be present in order to inhibit activation of
glucose uptake, L929 fibroblast cells were exposed to
150 μM verapamil, the minimum concentration that
completely inhibited activation, only during a 60-min time
period just prior to the 30-min treatment phase, or only during
the 30-min treatment phase, or only during the 10-min glucose
uptake phase.
To initiate each experiment, approximately 1.2×105 L929
fibroblast cells were plated into each well of a 24-well
culture-treated plate in 1.0 mL of low glucose (5.5 mM)
Dulbecco’s modified Eagle medium (DMEM) supplemented
with 10% fetal bovine serum and 1% penicillin/streptomycin.
The cells were grown overnight at 37°C in an incubator
supplied with humidified room air with 5% CO2. The next
day, the cells were rinsed with 0.2 mL of treatment media
and then incubated in 0.8 mL of fresh treatment media for
the 30 min at 37°C. For investigating the effects of verapamil
under basal conditions, the treatment media consisted of lowglucose DMEM containing 0, 50, 150, or 300 μM verapamil. For exploring the effects of verapamil on the ability to
activate GLUT1 by the glucose deprivation, the treatment
media consisted of glucose-free DMEM with 0, 50, 150, or
300 μM verapamil. To determine if calcium ion concentrations play a role in the effects of verapamil, the treatment
media consisted of glucose-free DMEM supplemented with
the effective inhibitory concentration of verapamil (150 μM)
plus either 5.0 mM CaCl2 to enhance calcium levels or
4.0 mM EDTA to lower calcium levels.
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Glucose uptake was then measured using radiolabeled 2deoxyglucose (2-DG) [23]. The media was replaced with
0.3 mL of glucose-free HEPES buffer (140 mM NaCl,
5 mM KCl, 20 mM HEPES/Na, pH=7.4, 2.5 mM MgSO4,
1 mM CaCl2, 2 mM NaPyr, 1 mM mannitol) containing the
same concentrations of verapamil, CaCl2, or EDTA that
were present in the treatment phase unless indicated
differently. This buffer was supplemented with 1.0 mM
(0.3 μCi/mL) 2-DG (1, 2-3H) and 1.0 mM (0.02 μCi/mL)
mannitol (1-14C). After 10-min incubation, cells were
briefly rinsed three times with cold glucose-free HEPES
to terminate uptake and remove excess radioactivity. The
cells were lysed by gentle shaking in 0.5 mL lyses buffer
(10 mM Tris, pH=7.4, 150 mM NaCl, 5 mM EDTA, 1.0%
triton X-100, 0.4% SDS). Cell contents were then completely digested by adjusting the solution to 0.5 M NaOH.
The mixture was then added to scintillation vials with
3.0 mL of Beckman Ready-Safe liquid scintillation cocktail. The 3H and 14C radioactivity was measured using a
Beckman LS 6500 liquid scintillation counter. Glucose
uptake was determined from the amount of 3H-2-DG
radioactivity isolated with the cells after subtracting out
the extracellular 3H-2-DG. The extracellular 3H-2-DG was
determined from the amount of 14C mannitol (not transported in these cells) that was also isolated with the cells
[22, 23, 28].

Results
Verapamil inhibited glucose uptake in a dose-dependent
manner under basal conditions reaching a statistically
significant reduction of over 50% at 300 μM verapamil
(reduction from 0.58±0.056 to 0.26±0.029 nmol10 min−1
well−1; see Fig. 1). Verapamil had a more dramatic
inhibitory affect on the activation of glucose transport by
glucose deprivation. Glucose deprivation of 30 min activated 2-DG uptake 322%, increasing it from 0.58±0.056 to
1.87±0.089 nmol10 min−1 well−1, but this activation was
inhibited by verapamil in a dose-dependent manner (see
Fig. 2). Complete inhibition of activation was achieved in
this experiment by 150 μM verapamil (0.49±0.028 compare to basal uptake of 0.58±0.056 nmol10 min−1 well−1).
Given the calcium channel blocking activity of verapamil,
we were curious to know if this inhibition of glucose
activation could be attributed to changes in calcium ion
concentrations. We investigated this indirectly by measuring the effects of either adding 5.0 mM CaCl2 to increase
calcium ion concentrations or 4.0 mM EDTA to lower
them. Neither of these agents alone significantly altered the
ability to stimulate L929 cells by glucose deprivation (data
not shown). In order to determine if altering calcium ion
concentrations using these agents altered verapamil’s
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inhibitory effects on the activation of glucose uptake,
glucose uptake was measured in L929 cells after a 30-min
exposure to glucose-free media with 150 μM verapamil
alone (a concentration which previously was shown to
completely inhibit activation of glucose uptake (see Fig. 2))
and in combination with either 5.0 mM CaCl2 or 4.0 mM
EDTA. The data are shown in Fig. 3 and are expressed as a
percent of stimulation, which was calculated by subtracting
basal glucose uptake from the activated uptake. The results
of this experiment indicate that 150 μM verapamil reduced
stimulation to 42.2% of maximum stimulation and that the
addition of Ca+2 or EDTA had no additional effect (41.4%
and 40.8%, respectively). It should be noted that the
inhibition of activation by 150 μM verapamil reported in
this experiment (about 60% inhibition) was not as extensive
as was reported in the dose-dependent experiment shown in
Fig. 2 (about 100% inhibition). This range of inhibitory
values can be attributed to differences is cell density that
occur from one experiment to the next.
To determine if verapamil was required to be present to
inhibit activation, L929 cells were exposed to 150 μM
verapamil either only during a 60-min pre-activation period,
or only during the 30-min glucose deprivation activation
period, or only during the 10-min glucose uptake period. As
seen from the data in Table 1, only exposure to verapamil
during the activation phase significantly inhibited activated
glucose uptake. Exposure to verapamil only during the 10min uptake tended to reduce uptake, but it was not
statistically significant. It should be noted that the degree
of inhibition by verapamil when present only during the
activation period was not as great as when it was included in
both the activation and uptake periods, approximately a 40%
reduction (Table 1) compared to a 60% (Fig. 3).

Fig. 1 Effects of verapamil on basal 2-DG uptake in L929 fibroblast
cells. Cells were incubated at 37°C for 30 min in low-glucose DMEM
supplemented with 0, 50, 150, or 300 μM verapamil as indicated. Tenminute 2-DG uptakes were then measured. Data values are displayed
on top as means ± SE for three samples from a representative
experiment. Significantly lower than control at *P=0.014
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Table 1 Effects of verapamil added at different times on 2-DG uptake
in L929 fibroblast cells
Experimental condition

2DG uptake
(nmol10 min−1 well−1)

Basal uptake (low-glucose media)
Activated uptake (no-glucose media)
Verapamil (150 μM) in pre-activation only
Verapamil (150 μM) in activation only
Verapamil (150 μM) in uptake only

Fig. 2 Effects of verapamil on activated 2-DG uptake in L929
fibroblast cells. Cells were incubated at 37°C for 30 min in glucosefree DMEM supplemented with 0, 50, 150, or 300 μM verapamil as
indicated. Ten-minute 2-DG uptakes were then measured. Data values
are displayed on top as means ± SE for samples of a representative
experiment. Significantly lower than control at *P<0.01

Discussion
Previous studies demonstrate that verapamil inhibits glucose
uptake in insulin-sensitive tissues such as adipocytes skeletal
myocytes and cardiac myocytes [3, 9, 26–28]. The mecha-

Fig. 3 Effects of Ca+2 and EDTA on the verapamil-inhibition of
activation of glucose uptake by glucose deprivation. L929 fibroblast
cells were incubated at 37°C for 30 min in glucose-free DMEM buffer
with no additions (Control), 150 μM verapamil (V), 150 μM verapamil
plus 5.0 mM Ca+2 (V+Ca), or 150 μM verapamil plus 4.0 mM EDTA
(V+EDTA). Ten-minute 2-DG uptakes were then measured. Data are
means ± SE for four samples of a representative experiment and
expressed as a percentage of the stimulated uptake. All three verapamil
conditions statistically decreased 2-DG uptake (P<0.01), but added
Ca+2 or EDTA had no additional effect

0.80±0.004
4.21±0.112
4.05±0.123
2.92±0.091*
3.92±0.162

Cells were incubated in a 60-min pre-activation period at 37°C
low-glucose DMEM buffer. No-glucose media were then added in
a 30-min activation period (except basal cells which received fresh
low-glucose media) followed by a 10-min 2-DG uptake period as
described in “Methods”; 150 μM verapamil was included only in
the pre-activation, activation, or uptake period as indicated. Data are
means ± SE for three wells of a representative experiment
*P<0.01, significantly lower than activated uptake

nism of this inhibition is largely unknown, but a recent study
in 3T3 adipocytes suggested that verapamil inhibits the
phosphorylation and activation of Akt, a downstream
mediator of the insulin-dependent PI3K signaling system
[3]. Others have suggested a more direct inhibition of the
GLUT transporters [28, 29]. However, the effects of
verapamil could not be assigned to a particular GLUT
transporter, since the cells used in all these studies expressed
multiple transporters. By using L929 fibroblast cells—a cell
line expresses only GLUT1 [32]—we were able to investigate the effects of verapamil on the transport activity of only
the GLUT1 transporters. The effects of verapamil on cells
containing only GLUT1 have not been reported. This
transporter is expressed in a wide variety of tissues and is
largely responsible for a basal level of glucose uptake. In
muscle tissue, a tissue that is largely responsible of whole
body glucose clearance, 25–40% of the transporters under
non-insulin conditions are GLUT1 [30, 31]. In addition,
there is accumulating evidence indicating that activity of
GLUT1 can be acutely activated by cell stress. Studies in
cells that express GLUT1 reveal that short-term exposure to
cell stressors such as hypoxia, hyperosmolarity, respiration
inhibitors, and glucose deprivation all activate glucose
uptake [21–25]. The data reported here reveal for the first
time that verapamil inhibits the glucose transport activity of
GLUT1 in a dose-dependent manner. The effects of
verapamil on basal glucose uptake are modest and reach
significance only at 300 μM verapamil. Previous work in
striated muscles has reported that concentrations of verapamil up to 200 μM did not affect basal glucose [28]. This is
not inconsistent with our observations. However, much more
dramatic are the effects of verapamil on the activation of
GLUT1 by cell stress (glucose deprivation). Activation of
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the transporter is completely inhibited by 150 μM verapamil
(Fig. 2). This effect does not appear to be dependent of the
drug’s calcium channel blocking properties, since adding
agents that would be expected to change concentrations of
calcium ions (5 mM CaCl2 or 4 mM EDTA) did not alter the
inhibitory effects of verapamil (Fig. 3). Inhibition of GLUT1
activity may be an important contributor to the toxic effects
of CCB. In addition to inhibiting insulin-sensitive glucose
uptake as noted in previous studies, CCBs may also both
inhibit GLUT1 as well as prevent the activation of this
transporter that normally occurs under stress. Given the
observed hyperglycemia that accompanies CCB toxicity, the
cellular stress provided in these studies, glucose deprivation,
is likely not the cellular stress expected. Nevertheless, given
that there are multiple stressors that activate GLUT1 and it is
not unreasonable to expect that in a CCB toxic event, cells
would experience stress and CCBs may prevent the normal
activation of this transporter. Interestingly, verapamil had to
be present during the activation phase (glucose deprivation)
to be inhibitory. A pre-incubation and removal of verapamil
did not prevent the activation of glucose uptake (see Table 1).
This suggests a direct interaction of verapamil with a
component of the activation process. However, that interaction may not be with the GLUT1 protein itself, since
incubation with verapamil only during the uptake period did
not prevent the activation of transport by glucose deprivation
(Table 1). This matches results from a previous study, which
reported that the transport activity of GLUT1 reconstituted in
liposomes was not inhibited by verapamil [33].
The detailed mechanism of the activation of GLUT1 is
currently unknown. However, there are two plausible final
steps in the activation process that have been proposed.
Rubin and Ismail-Beigi have proposed that activation of
glucose uptake by cell stress triggers a movement of
GLUT1 to lipid rafts where the change in lipid environment
activates the transporter [24]. On the other hand, Carruthers
has suggested that the activation of GLUT1 in erythrocytes
is triggered by a formation of tetramers [34]. Our data
suggest that verapamil interferes primarily with the activation process rather than with the transporter itself, but the
details are not yet delineated.

Conclusion
This study reveals the unique finding that verapamil in a
dose-dependent manner has an inhibitory effect on both the
basal activity and the stress-activated transport activity of
GLUT1. The inhibition of GLUT1 may be a contributing
factor to the hyperglycemia observed in CCB poisoning.
Acknowledgment Special thanks to Dr. Laura Bechtel for her
review and critique of the manuscript.
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